<?xml version='1.0' encoding='utf-8'?>
<document id="28408803"><sentence text="Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer."><entity charOffset="52-62" id="DDI-PubMed.28408803.s1.e0" text="omeprazole" /></sentence><sentence text="A microdose drug-drug interaction (DDI) study may be a valuable tool for anticipating drug interaction at therapeutic doses" /><sentence text=" This study aimed to compare the magnitude of DDIs at microdoses and regular doses to explore the applicability of a microdose DDI study" /><sentence text="" /><sentence text="Six healthy male volunteer subjects were enrolled into each DDI study of omeprazole (victim) and known perpetrators: fluconazole (inhibitor) and rifampin (inducer)"><entity charOffset="73-83" id="DDI-PubMed.28408803.s5.e0" text="omeprazole" /><entity charOffset="117-128" id="DDI-PubMed.28408803.s5.e1" text="fluconazole" /><entity charOffset="145-153" id="DDI-PubMed.28408803.s5.e2" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.28408803.s5.e0" e2="DDI-PubMed.28408803.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28408803.s5.e0" e2="DDI-PubMed.28408803.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28408803.s5.e0" e2="DDI-PubMed.28408803.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28408803.s5.e1" e2="DDI-PubMed.28408803.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28408803.s5.e1" e2="DDI-PubMed.28408803.s5.e2" /></sentence><sentence text=" For both studies, the microdose (100 Î¼g, cold compound) and the regular dose (20 mg) of omeprazole were given at days 0 and 1, respectively"><entity charOffset="89-99" id="DDI-PubMed.28408803.s6.e0" text="omeprazole" /></sentence><sentence text=" On days 2-9, the inhibitor or inducer was given daily, and the microdose and regular dose of omeprazole were repeated at days 8 and 9, respectively"><entity charOffset="94-104" id="DDI-PubMed.28408803.s7.e0" text="omeprazole" /></sentence><sentence text=" Full omeprazole pharmacokinetic samplings were performed at days 0, 1, 8, and 9 of both studies for noncompartmental analysis"><entity charOffset="6-16" id="DDI-PubMed.28408803.s8.e0" text="omeprazole" /></sentence><sentence text="" /><sentence text="The magnitude of the DDI, the geometric mean ratios (with perpetrator/omeprazole only) of maximum concentration (Cmax) and area under the curve to the last measurement (AUCt) of the microdose and the regular dose were compared"><entity charOffset="70-80" id="DDI-PubMed.28408803.s10.e0" text="omeprazole" /></sentence><sentence text=" The geometric mean ratios in the inhibition study were: 2" /><sentence text="17 (micro) and 2" /><sentence text="68 (regular) for Cmax, and 4" /><sentence text="07 (micro), 4" /><sentence text="33 (regular) for AUCt" /><sentence text=" For the induction study, they were 0" /><sentence text="26 (micro) and 0" /><sentence text="21 (regular) for Cmax, and 0" /><sentence text="16 (micro) and 0" /><sentence text="15 (regular) for AUCt" /><sentence text=" There were no significant statistical differences in the magnitudes of DDIs between microdose and regular-dose conditions, regardless of induction or inhibition" /><sentence text="" /><sentence text="Our results may be used as partial evidence that microdose DDI studies may replace regular-dose studies, or at least be used for DDI-screening purposes" /><sentence text="" /></document>